Xarelto for VTE Prophylaxis After Hip or Knee Arthroplasty

• Status: Completed
• Trial end date: 2013-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The main goal is to provide additional information to the risk-benefit assessment of the drug.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer
• Collaborator: Janssen Research & Development, LLC
• Treatments: Rivaroxaban

Criteria

Inclusion Criteria:

• Female and male patients who will undergo elective hip or knee arthroplasty.

Exclusion Criteria:

• Exclusion criteria must be read in conjunction with the local product information.